Advertisement

Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study

Published:August 27, 2022DOI:https://doi.org/10.1016/j.msard.2022.104151

      Highlights

      • Currently, few studies that have investigated the prevalence of MS in China based on the latest diagnostic criteria.
      • The case ascertainment procedures of case finding combined with face-to-face diagnosis by experts is more probable to improve the accuracy of this study.
      • Accurate estimates of the prevalence of multiple sclerosis can inform the rational allocation of public health resources.

      Abstract

      Background

      Multiple sclerosis (MS) is rare in China, and the prevalence previously reported may be biased. Currently, few studies that have investigated the prevalence of MS in China based on the latest diagnostic criteria.

      Methods

      Through a population-based survey from August 8, 2021 to December 31, 2021, we calculated the prevalence of multiple sclerosis in 18,676,605 residents of Guangzhou, China. MS patients were identified through the health insurance system of the Guangzhou Health Insurance Bureau, and we surveyed 17 large tertiary hospitals using a case-finding approach. All MS patients were diagnosed according to the 2017 McDonald criteria.

      Results

      A total of 143 patients in the resident population of Guangzhou were diagnosed with MS, with a crude prevalence of 0.77 per 100,000 (95% confidence interval (CI): 0.65-0.90), and the prevalence was higher in in females (1.14/100,000) than in males (0.44/100,000). The age-adjusted prevalence was 0.92 per 100,000 (95% CI: 0.77-1.10). The prevalence peaked at the age of 25-29 years (2.86/100,000) for both males and females (1.44/100,000 and 4.42/100,000, respectively).

      Conclusions

      This is the first study to report the prevalence of MS in Guangzhou, China, according to the criteria. Our study shows that the prevalence of MS in Guangzhou is lower than that in other cities in China.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bebo B.
        • Cintina I.
        • LaRocca N.
        • Ritter L.
        • Talente B.
        • Hartung D.
        • Ngorsuraches S.
        • Wallin M.
        • Yang G.
        The economic burden of multiple sclerosis in the united states: estimate of direct and indirect costs.
        Neurology. 2022; 98: e1810-e1817
        • Cheng Q.
        • Miao L.
        • Zhang J.
        • Ding S.J.
        • Liu Z.G.
        • Wang X.
        • Sun X.J.
        • Zhao Z.X.
        • Song Y.J.
        • Ding X.Y.
        • Guo Z.L.
        • Yang Y.
        • Chen S.D.
        • Jiang G.X.
        • Fredrikson S.
        A population-based survey of multiple sclerosis in Shanghai, China.
        Neurology. 2007; 68: 1495-1500
        • China, N.H.a.W.C.o.t.P.s.R.o.
        China Smoking Health Risk Report 2020.
        2020
        • Dobson R.
        • Ramagopalan S.
        • Davis A.
        • Giovannoni G.
        Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude.
        J. Neurol. Neurosurg. Psychiatry. 2013; 84: 909-914
        • Eskandarieh S.
        • Allahabadi N.S.
        • Sadeghi M.
        • Sahraian M.A.
        Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015.
        BMC Neurol. 2018; 18: 15
        • Fang C.W.
        • Wang H.P.
        • Chen H.M.
        • Lin J.W.
        • Lin W.S.
        Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015.
        Mult. Scler. Relat. Disord. 2020; 45102425
        • Feinstein A.
        • Magalhaes S.
        • Richard J.F.
        • Audet B.
        • Moore C.
        The link between multiple sclerosis and depression.
        Nat. Rev. Neurol. 2014; 10: 507-517
        • Gamage S.M.K.
        • Wijeweera I.
        • Adikari S.B.
        • Fink K.
        • Hillert J.
        • Fogdell-Hahn A.
        • Sominanda H.M.A.
        Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.
        Mult. Scler. Int. 2018. 2018; 5342936
      1. Guangzhou Bureau of Statistics, 2021. 2021 Statistical Yearbook, Guangzhou City.

        • Jongen P.J.
        • Ter Horst A.T.
        • Brands A.M.
        Cognitive impairment in multiple sclerosis.
        Minerva Med. 2012; 103: 73-96
        • Kalb R.
        • Feinstein A.
        • Rohrig A.
        • Sankary L.
        • Willis A.
        Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations.
        Curr. Neurol. Neurosci. Rep. 2019; 19: 77
        • Kira J.
        Multiple sclerosis in the Japanese population.
        Lancet Neurol. 2003; 2: 117-127
        • Lau K.K.
        • Wong W.W.
        • Sheng B.
        • Yu I.T.
        • Fung B.H.
        • Li H.L.
        • Ma K.F.
        • Wong L.K.
        • Li P.C.
        The clinical course of multiple sclerosis patients in Hong Kong.
        J. Neurol. Sci. 2008; 268: 78-82
        • Lauritsen JM
        • Bruus M
        EpiData (version 3). A comprehensive tool for validated entry and documentation of data.
        The EpiData Association, Odense Denmark2003
        • Lechner-Scott J.
        • Spencer B.
        • de Malmanche T.
        • Attia J.
        • Fitzgerald M.
        • Trojano M.
        • Grand'Maison F.
        • Gomez J.A.
        • Izquierdo G.
        • Duquette P.
        • Girard M.
        • Grammond P.
        • Oreja-Guevara C.
        • Hupperts R.
        • Bergamaschi R.
        • Boz C.
        • Giuliani G.
        • van Pesch V.
        • Iuliano G.
        • Fiol M.
        • Cristiano E.
        • Verheul F.
        • Saladino M.L.
        • Slee M.
        • Barnett M.
        • Deri N.
        • Flechter S.
        • Vella N.
        • Shaw C.
        • Herbert J.
        • Moore F.
        • Petkovska-Boskova T.
        • Jokubaitis V.
        • Butzkueven H.
        The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.
        Mult. Scler. 2012; 18: 974-982
        • Lennon V.A.
        • Wingerchuk D.M.
        • Kryzer T.J.
        • Pittock S.J.
        • Lucchinetti C.F.
        • Fujihara K.
        • Nakashima I.
        • Weinshenker B.G.
        A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
        Lancet. 2004; 364: 2106-2112
        • Liu X.
        • Cui Y.
        • Han J.
        Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China.
        Orphanet J Rare Dis. 2016; 11: 73
        • Liu Y.
        • Zhao G.
        • Yu H.
        • Lyu C.
        • Li Z.
        • Wu Z.
        Differentiation of neuromyelitis optica from multiple sclerosis in a cohort from the mainland of China.
        Chin. Med. J. (Engl.). 2014; 127: 3213-3218
        • Lu T.
        • Zhao L.
        • Sun X.
        • Au C.
        • Huang Y.
        • Yang Y.
        • Bao J.
        • Wu A.
        • Kermode A.G.
        • Qiu W.
        • Lau A.Y.
        Comparison of multiple sclerosis patients with and without oligoclonal IgG bands in South China.
        J. Clin. Neurosci. 2019; 66: 51-55
        • Maguire R.
        • Maguire P.
        Caregiver burden in multiple sclerosis: recent trends and future directions.
        Curr. Neurol. Neurosci. Rep. 2020; 20: 18
        • Max G Griswold N.F.
        • Hawley Caitlin
        • Arian Nicholas
        • Zimsen Stephanie R M
        Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet. 2018; 392: 1015-1035
        • McDonald W.I.
        • Compston A.
        • Edan G.
        • Goodkin D.
        • Hartung H.P.
        • Lublin F.D.
        • McFarland H.F.
        • Paty D.W.
        • Polman C.H.
        • Reingold S.C.
        • Sandberg-Wollheim M.
        • Sibley W.
        • Thompson A.
        • van den Noort S.
        • Weinshenker B.Y.
        • Wolinsky J.S.
        Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
        Ann. Neurol. 2001; 50: 121-127
        • Poser C.M.
        • Paty D.W.
        • Scheinberg L.
        • McDonald W.I.
        • Davis F.A.
        • Ebers G.C.
        • Johnson K.P.
        • Sibley W.A.
        • Silberberg D.H.
        • Tourtellotte W.W.
        New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
        Ann. Neurol. 1983; 13: 227-231
      2. R Core Team, 2019. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

        • Reinhardt K.
        • Weiss S.
        • Rosenbauer J.
        • Gärtner J.
        • von Kries R.
        Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011).
        Eur. J. Neurol. 2014; 21: 654-659
        • Sackett D.L.
        • Holland W.W.
        Controversy in the detection of disease.
        Lancet. 1975; 2: 357-359
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • Correale J.
        • Fazekas F.
        • Filippi M.
        • Freedman M.S.
        • Fujihara K.
        • Galetta S.L.
        • Hartung H.P.
        • Kappos L.
        • Lublin F.D.
        • Marrie R.A.
        • Miller A.E.
        • Miller D.H.
        • Montalban X.
        • Mowry E.M.
        • Sorensen P.S.
        • Tintoré M.
        • Traboulsee A.L.
        • Trojano M.
        • Uitdehaag B.M.J.
        • Vukusic S.
        • Waubant E.
        • Weinshenker B.G.
        • Reingold S.C.
        • Cohen J.A.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Topcu G.
        • Griffiths H.
        • Bale C.
        • Trigg E.
        • Clarke S.
        • Potter K.J.
        • Mhizha-Murira J.R.
        • Drummond A.
        • Evangelou N.
        • Fitzsimmons D.
        • das Nair R.
        Psychosocial adjustment to multiple sclerosis diagnosis: A meta-review of systematic reviews.
        Clin. Psychol. Rev. 2020; 82101923
        • Viswanathan S.
        • Rose N.
        • Arip M.
        • Chai C.H.
        • Law W.C.
        • Sim R.
        • Ong M.C.
        Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: A comparison in different ethnic groups.
        Mult. Scler. Relat. Disord. 2018; 25: 300-308